Treatment of Refractory Ovarian Cancer with 5-Fluorouracil and Leucovorin
The objective of this study was to evaluate the activity of the combination of 5-fluorouracil (5-FU) and leucovorin in women with platinum-resistant recurrent or advanced ovarian cancer. A retrospective study was conducted of consecutive patients treated with weekly intravenous 5-FU and leucovorin, both at 500 mg/m 2 . Sixty-one cycles were administered to 28 women between 1989 and 1995. The median age of the patients was 58 years and median number of previous chemotherapy regimens was 2. No patient had a complete response. There was 1 partial response (PR) among 8 patients with measurable disease, and 4 PR among 20 women with evaluable disease; 2 had stable disease and 21 progressed on treatment for a response rate of 18% (95% confidence interval, 3-33%). Duration of response was 2 to 14 months, median 5 months. Survival from the start of 5-FU/leucovorin ranged from 1 to 78 months, median 5.5 months, and a mean of 10 +/- 15 months (mean +/- SD). The combination of 5-FU/leucovorin had minimal activity in this patient population. Only 2 women achieved resolution of their ascites and experienced a significant palliation.
유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.
원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.
NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.
- 이 논문과 함께 출판된 논문 + 더보기